Compare ESQ & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | BBNX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 897.6M |
| IPO Year | 2017 | 2025 |
| Metric | ESQ | BBNX |
|---|---|---|
| Price | $131.90 | $16.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $142.67 | $25.10 |
| AVG Volume (30 Days) | 128.7K | ★ 1.1M |
| Earning Date | 10-27-2026 | 10-27-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | 14.20 | ★ 78.95 |
| EPS | ★ 4.48 | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | $53.78 | $25.22 |
| Revenue Next Year | $47.38 | $47.09 |
| P/E Ratio | $29.46 | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $94.55 | $8.80 |
| 52 Week High | $134.65 | $32.71 |
| Indicator | ESQ | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 63.82 | 45.41 |
| Support Level | $113.87 | $15.40 |
| Resistance Level | $133.94 | $18.20 |
| Average True Range (ATR) | 4.06 | 1.62 |
| MACD | 0.54 | -0.00 |
| Stochastic Oscillator | 76.60 | 25.71 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.